These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9447336)

  • 1. Clinical trial results with a new plasminogen activator.
    Bode C; Peter K; Moser M; Smalling RW; Weaver WD
    Eur Heart J; 1997 Dec; 18 Suppl F():F17-21. PubMed ID: 9447336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patency trials with reteplase (r-PA): what do they tell us?
    Bode C; Nordt TK; Peter K; Smalling RW; Runge MS; Kübler W
    Am J Cardiol; 1996 Dec; 78(12A):16-9. PubMed ID: 8990406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.
    Bode C; Smalling RW; Berg G; Burnett C; Lorch G; Kalbfleisch JM; Chernoff R; Christie LG; Feldman RL; Seals AA; Weaver WD
    Circulation; 1996 Sep; 94(5):891-8. PubMed ID: 8790022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of thrombolytic drugs in the management of myocardial infarction. Comparative clinical trials.
    Weaver WD
    Eur Heart J; 1996 Dec; 17 Suppl F():9-15. PubMed ID: 8960443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
    Smalling RW; Bode C; Kalbfleisch J; Sen S; Limbourg P; Forycki F; Habib G; Feldman R; Hohnloser S; Seals A
    Circulation; 1995 Jun; 91(11):2725-32. PubMed ID: 7758177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reteplase. A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction.
    Noble S; McTavish D
    Drugs; 1996 Oct; 52(4):589-605. PubMed ID: 8891469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trials in thrombolytic therapy, Part 2: The open-artery hypothesis and RAPID-1 and RAPID-2.
    Lopez LM
    Am J Health Syst Pharm; 1997 Nov; 54 Suppl 1():S27-30. PubMed ID: 9397235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reteplase: a new thrombolytic for the treatment of acute myocardial infarction.
    Wooster MB; Luzier AB
    Ann Pharmacother; 1999 Mar; 33(3):318-24. PubMed ID: 10200858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current clinical use of reteplase for thrombolysis. A pharmacokinetic-pharmacodynamic perspective.
    Martin U; Kaufmann B; Neugebauer G
    Clin Pharmacokinet; 1999 Apr; 36(4):265-76. PubMed ID: 10320949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spotlight on reteplase in thrombotic occlusive disorders.
    Simpson D; Siddiqui MA; Scott LJ; Hilleman DE
    BioDrugs; 2007; 21(1):65-8. PubMed ID: 17263591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet function and fibrinolytic agents: two sides of a coin?
    Callahan KP; Malinin AI; Gurbel PA; Alexander JH; Granger CB; Serebruany VL
    Cardiology; 2001; 95(2):55-60. PubMed ID: 11423707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trials in thrombolytic therapy: what do they tell us? INJECT 6-month outcomes data.
    Wilcox RG
    Am J Cardiol; 1996 Dec; 78(12A):20-3. PubMed ID: 8990407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reteplase: a review of its use in the management of thrombotic occlusive disorders.
    Simpson D; Siddiqui MA; Scott LJ; Hilleman DE
    Am J Cardiovasc Drugs; 2006; 6(4):265-85. PubMed ID: 16913828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics.
    Lancet; 1995 Aug; 346(8971):329-36. PubMed ID: 7623530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled trials comparing reteplase with alteplase and streptokinase in patients with acute myocardial infarction.
    Amsterdam EA
    Pharmacotherapy; 1996; 16(5 Pt 2):137S-140S. PubMed ID: 8888101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial.
    Topol EJ; Ohman EM; Armstrong PW; Wilcox R; Skene AM; Aylward P; Simes J; Dalby A; Betriu A; Bode C; White HD; Hochman JS; Emanuelson H; Vahanian A; Sapp S; Stebbins A; Moliterno DJ; Califf RM
    Circulation; 2000 Oct; 102(15):1761-5. PubMed ID: 11023929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of the RAPID 1 and RAPID 2 thrombolytic trials in acute myocardial infarction.
    Weaver WD
    Eur Heart J; 1996 Sep; 17 Suppl E():14-20. PubMed ID: 11823998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries.
    Gurbel PA; Serebruany VL; Shustov AR; Bahr RD; Carpo C; Ohman EM; Topol EJ
    J Am Coll Cardiol; 1998 Jun; 31(7):1466-73. PubMed ID: 9626821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological and clinical impact of the unique molecular structure of a new plasminogen activator.
    Smalling RW
    Eur Heart J; 1997 Dec; 18 Suppl F():F11-6. PubMed ID: 9447335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reteplase: new preparation. Minimal value: bolus versus infusion.
    Prescrire Int; 1998 Jun; 7(35):73-4. PubMed ID: 10342921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.